FibroGen (FGEN)
(Delayed Data from NSDQ)
$0.39 USD
0.00 (1.23%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $0.39 0.00 (-1.22%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for FibroGen, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 236 | 422 | 405 | 687 | 534 |
Receivables | 13 | 16 | 17 | 42 | 28 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 42 | 40 | 31 | 17 | 7 |
Other Current Assets | 42 | 14 | 20 | 10 | 133 |
Total Current Assets | 332 | 493 | 474 | 755 | 702 |
Net Property & Equipment | 13 | 21 | 28 | 34 | 43 |
Investments & Advances | 5 | 9 | 172 | 3 | 61 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 7 | 8 | 6 | 11 |
Total Assets | 424 | 610 | 774 | 827 | 857 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 18 | 31 | 26 | 25 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 12 | 12 |
Accrued Expenses | 173 | 220 | 173 | 120 | 84 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 13 | 13 | 16 | 7 | 0 |
Total Current Liabilities | 218 | 274 | 226 | 163 | 103 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 158 | 186 | 187 | 138 | 99 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 72 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 25 | 38 |
Other Non-Current Liabilities | 72 | 73 | 44 | 58 | 81 |
Minority Interest (Liabilities) | 21 | 0 | 0 | 0 | 0 |
Total Liabilities | 607 | 612 | 545 | 385 | 322 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 1,644 | 1,541 | 1,476 | 1,400 | 1,301 |
Retained Earnings | -1,842 | -1,558 | -1,264 | -974 | -785 |
Other Equity | 14 | 14 | 16 | 15 | 19 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -184 | -1 | 229 | 441 | 535 |
Total Liabilities & Shareholder's Equity | 424 | 610 | 774 | 827 | 857 |
Total Common Equity | -184 | -1 | 229 | 441 | 535 |
Shares Outstanding | 98.30 | 93.90 | 92.70 | 91.00 | 87.20 |
Book Value Per Share | -1.87 | -0.02 | 2.47 | 4.85 | 6.14 |
Fiscal Year End for FibroGen, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 141 | 178 | 236 | 251 | 336 |
Receivables | 6 | 37 | 13 | 32 | 26 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 25 | 27 | 42 | 41 | 41 |
Other Current Assets | 37 | 36 | 42 | 40 | 9 |
Total Current Assets | 209 | 278 | 332 | 364 | 411 |
Net Property & Equipment | 11 | 12 | 13 | 15 | 17 |
Investments & Advances | 7 | 6 | 5 | 5 | 6 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 5 | 5 | 6 | 6 |
Total Assets | 293 | 366 | 424 | 460 | 515 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 4 | 18 | 19 | 13 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 114 | 164 | 173 | 171 | 163 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 10 | 13 | 13 | 7 | 7 |
Total Current Liabilities | 149 | 197 | 218 | 209 | 194 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 131 | 147 | 158 | 154 | 165 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 72 | 72 | 72 | 72 | 71 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 73 | 72 | 70 | 71 | |
Minority Interest (Liabilities) | 21 | 21 | 21 | 21 | 21 |
Total Liabilities | 505 | 574 | 607 | 597 | 597 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 1,661 | 1,652 | 1,644 | 1,634 | 1,625 |
Retained Earnings | -1,890 | -1,875 | -1,842 | -1,786 | -1,722 |
Other Equity | 17 | 14 | 14 | 14 | 14 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -212 | -208 | -184 | -137 | -82 |
Total Liabilities & Shareholder's Equity | 293 | 366 | 424 | 460 | 515 |
Total Common Equity | -212 | -208 | -184 | -137 | -82 |
Shares Outstanding | 99.40 | 99.40 | 98.30 | 98.20 | 97.50 |
Book Value Per Share | -2.13 | -2.09 | -1.87 | -1.39 | -0.84 |